{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-006795","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.101313+00:00","generated_at":"2026-06-08T14:33:57.794381+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arbutus Biopharma CEO William Collier to retire Dec 31; COO McElhaugh named interim CEO","bullets":["William H. Collier retires as President, CEO, and director effective Dec 31, 2023.","Michael J. McElhaugh, Co-founder and COO, appointed interim President and CEO effective Jan 1, 2024.","McElhaugh will also join the Board on Jan 1, 2024.","Collier's retirement is not due to any disagreement with the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-006795","json":"https://secwatch.observer/filing/0001171843-23-006795.json","markdown":"https://secwatch.observer/filing/0001171843-23-006795.md","text":"https://secwatch.observer/filing/0001171843-23-006795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323006795/0001171843-23-006795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323006795/f8k_110723.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:33:57.794381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bfe462d06","claim":"William H. Collier retired as President and Chief Executive Officer at Arbutus Biopharma Corp.","evidence_excerpt":"On November 1, 2023, William H. Collier informed Arbutus Biopharma Corporation (the “Company”) of his retirement as the Company’s Chief Executive Officer (“CEO”) and from the Board of Directors (the “Board”) of the Company, effective as of December 31, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323006795/0001171843-23-006795-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"393eac47a2","claim":"Michael J. McElhaugh was appointed as Interim President and Chief Executive Officer at Arbutus Biopharma Corp.","evidence_excerpt":"the Board appointed Michael J. McElhaugh, Co-founder and Chief Operating Officer of the Company, as interim President and CEO, effective January 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323006795/0001171843-23-006795-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}